Novel diagnostic biomarkers for prostate cancer
نویسندگان
چکیده
منابع مشابه
Novel diagnostic biomarkers for prostate cancer
Prostate cancer is the most frequently diagnosed malignancy in American men, and a more aggressive form of the disease is particularly prevalent among African Americans. The therapeutic success rate for prostate cancer can be tremendously improved if the disease is diagnosed early. Thus, a successful therapy for this disease depends heavily on the clinical indicators (biomarkers) for early dete...
متن کاملCurrent early diagnostic biomarkers of prostate cancer
Prostate cancer (PCa) has become to have the highest incidence and the second mortality rate in western countries, affecting men's health to a large extent. Although prostate-specific antigen (PSA) was discovered to help diagnose the cancer in an early stage for decades, its specificity is relative low, resulting in unnecessary biopsy for healthy people and over-treatment for patients. Thus, it...
متن کاملProstasomes as a source of diagnostic biomarkers for prostate cancer
Introduction Prostate cancer (PCa) is the most frequent cancer type diagnosed in men, with a yearly incidence of approximately 382,000 cases, resulting in 89,000 deaths in 2008 in Europe alone (1). The mortality of men diagnosed with PCa varies greatly between countries but, on average, has declined over the years. This decline is attributed to both increased detection of latent disease and imp...
متن کاملProstasomes as a source of diagnostic biomarkers for prostate cancer.
New biomarkers are needed to improve the diagnosis of prostate cancer. Similarly to healthy cells, prostate epithelial cancer cells produce extracellular vesicles (prostasomes) that can be isolated from seminal fluid, urine, and blood. Prostasomes contain ubiquitously expressed and prostate-specific membrane and cytosolic proteins, as well as RNA. Both quantitative and qualitative changes in pr...
متن کاملNovel biomarkers for the detection of prostate cancer
Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate cancer and for decision making regarding treatment options, response to therapy, and clinical follow-up. Despite its widespread use, it is well recognised that PSA has suboptimal performance as a screening tool due to poor specificity, resulting in high negative biopsy rates and potential 'over-diagnosis'...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer
سال: 2010
ISSN: 1837-9664
DOI: 10.7150/jca.1.150